hotspot -WSS

hotspot

author：Wikipedia 2025-09-28 11:45:18 - browse：8228

Adam's take main illustration — Molly Ferguson/STAT

The approval Friday of Bluebird Bio’s gene therapy for sickle cell disease should have been a momentum-swinging achievement for the long-struggling biotech. Instead, the company mispriced its new drug and fumbled a pivotal financial lifeline.

The consequences of these strategic blunders — arguably, self-inflicted — could imperil Bluebird’s independence, perhaps even its survival.

Bluebird priced Lyfgenia at $3.1 million, while Vertex Pharmaceutical set the cost of Casgevy, its competing sickle cell treatment also approved on Friday, at $2.2 million. Not only is Lyfgenia significantly more expensive, but its prescribing label carries a “black box” safety warning, which requires patients undergo regular blood monitoring for cancer risk. Casgevy has no similar monitoring requirement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Study: Spinal cord stimulation helps patients with paralysis walk again

entertainment

WSS

FDA greenlights medical device to combat bladder issues

Senators start work on Medicare physician payment reform

CDC says it’s too soon to assess risk posed by Covid subvariant

Vaccine advisory panel ACIP left half staffed by HHS

Abortion policy in the spotlight at Republican debate

Health officials lay out plans to cope with respiratory virus season

leisure time

hotspot

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

CDC says it’s too soon to assess risk posed by Covid subvariant

Drug repurposing or repositioning? The language matters

Vivek Ramaswamy made waves in the debate, much as in biotech

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

CDC says it’s too soon to assess risk posed by Covid subvariant

Psychedelics group wrestles with new pharma identity

'Revelatory' study finds a smoking impact that remains after quitting

In age of alternative facts, a scholarly course on calling out crap

Senators start work on Medicare physician payment reform

knowledge

California store owner shot dead in dispute over displaying Pride flag: Police

PBMs are inflating the cost of generic drugs. They must be reined in

Why did Pfizer dish out millions for a Super Bowl ad?

Study: Spinal cord stimulation helps patients with paralysis walk again

Health officials lay out plans to cope with respiratory virus season

Intellia plays down concerns on accidental germline transmission

entertainment

entertainment

leisure time

hotspot